Ionis Pharmaceuticals - IONS Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $56.08
Forecasted Upside: 34.83%
Number of Analysts: 13
Breakdown:
1 Sell Ratings
3 Hold Ratings
8 Buy Ratings
1 Strong Buy Ratings

^$41.59 As of 04/26/2024 01:00 AM ET

▼ -0.25 (-0.60%)

1 month | 3 months | 12 months

Get New Ionis Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for IONS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IONS

^$56.08

▲ +34.83% Upside Potential

This price target is based on 13 analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. The average price target is $56.08, with a high forecast of $75.00 and a low forecast of $28.00. The average price target represents a 34.83% upside from the last price of $41.59.

Current Consensus is Moderate Buy

The current consensus among 13 investment analysts is to moderate buy stock in Ionis Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

1 strong buy ratings
8 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

11/4/2022

1 strong buy ratings
8 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

2/2/2023

1 strong buy ratings
8 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

5/3/2023

1 strong buy ratings
8 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

8/1/2023

1 strong buy ratings
8 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

10/30/2023

1 strong buy ratings
8 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

1/28/2024

1 strong buy ratings
8 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

3/28/2024

1 strong buy ratings
8 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

4/27/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/10/2024	Wolfe Research	Upgrade	Peer Perform ➝ Outperform	$58.00	Low
4/9/2024	William Blair	Reiterated Rating	Outperform		Low
4/9/2024	Oppenheimer	Boost Target	Outperform ➝ Outperform	$72.00 ➝ $75.00	Low
4/9/2024	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$60.00	Low
3/6/2024	Oppenheimer	Boost Target	Outperform ➝ Outperform	$65.00 ➝ $72.00	Low
2/26/2024	Oppenheimer	Reiterated Rating	Outperform	$63.00 ➝ $65.00	Low
2/22/2024	Piper Sandler	Boost Target	Overweight ➝ Overweight	$62.00 ➝ $63.00	Low
2/22/2024	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$60.00	Low
2/1/2024	JPMorgan Chase & Co.	Boost Target	Neutral ➝ Neutral	$52.00 ➝ $55.00	Low
1/26/2024	Royal Bank of Canada	Boost Target	Outperform ➝ Outperform	$65.00 ➝ $70.00	Low
1/18/2024	Piper Sandler	Boost Target	Overweight ➝ Overweight	$60.00 ➝ $62.00	Low
1/2/2024	Bank of America	Upgrade	Neutral ➝ Buy	$52.00 ➝ $62.00	Low
12/19/2023	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$60.00	Low
12/18/2023	Stifel Nicolaus	Boost Target	Hold ➝ Hold	$45.00 ➝ $50.00	Low
11/17/2023	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$60.00	Low
11/13/2023	William Blair	Reiterated Rating	Outperform		Low
11/3/2023	The Goldman Sachs Group	Boost Target	Sell ➝ Sell	$25.00 ➝ $28.00	Low
11/3/2023	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$45.00 ➝ $48.00	Low
10/23/2023	Bank of America	Upgrade	Underperform ➝ Neutral	$33.00 ➝ $52.00	Low
10/5/2023	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$65.00	Low
9/28/2023	Raymond James	Initiated Coverage	Strong-Buy	$63.00	Low
9/27/2023	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $45.00	Low
9/27/2023	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$60.00	Low
8/10/2023	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$60.00	N/A
7/31/2023	Citigroup	Upgrade	Neutral ➝ Buy	$36.00 ➝ $60.00	Low
5/4/2023	VNET Group	Reiterated Rating	Maintains		Low
5/4/2023	Citigroup	Upgrade	Sell ➝ Neutral	$30.00 ➝ $36.00	Low
5/4/2023	Barclays	Lower Target		$40.00 ➝ $37.00	Low
4/11/2023	Morgan Stanley	Boost Target	Equal Weight	$40.00 ➝ $42.00	Low
3/21/2023	Sanford C. Bernstein	Initiated Coverage	Underperform	$31.00	Low
2/23/2023	SVB Leerink	Lower Target	Market Perform	$34.00 ➝ $27.00	Low
2/23/2023	Royal Bank of Canada	Reiterated Rating	Outperform	$65.00	Low
2/23/2023	SVB Securities	Lower Target		$34.00 ➝ $27.00	Low
2/23/2023	Needham & Company LLC	Reiterated Rating	Buy	$60.00	Low
2/23/2023	BMO Capital Markets	Lower Target	Outperform	$70.00 ➝ $67.00	Low
2/23/2023	Barclays	Lower Target	Equal Weight	$44.00 ➝ $40.00	Low
2/3/2023	SVB Leerink	Boost Target	Market Perform	$33.00 ➝ $34.00	Low
1/23/2023	SVB Leerink	Boost Target	Market Perform	$32.00 ➝ $33.00	Low
1/19/2023	Piper Sandler	Boost Target	Overweight	$60.00 ➝ $62.00	Low
12/21/2022	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$56.00 ➝ $40.00	Low
11/15/2022	Barclays	Boost Target		$44.00	Low
11/10/2022	Morgan Stanley	Lower Target	Overweight	$57.00 ➝ $56.00	Low
11/10/2022	SVB Leerink	Lower Target	Market Perform	$30.00 ➝ $26.00	Low
11/10/2022	Citigroup	Boost Target	Sell	$28.00 ➝ $31.00	Low
11/9/2022	Piper Sandler	Boost Target		$58.00 ➝ $60.00	Low
9/9/2022	Morgan Stanley	Upgrade	Underweight ➝ Overweight	$30.00 ➝ $57.00	Low
8/10/2022	Citigroup	Boost Target	Sell	$26.00 ➝ $28.00	Low
7/26/2022	Piper Sandler	Boost Target	Overweight	$55.00 ➝ $58.00	Low
7/18/2022	Oppenheimer	Reiterated Rating	Outperform	$59.00	Low
6/21/2022	SVB Leerink	Boost Target	Market Perform	$26.00 ➝ $27.00	Low
6/10/2022	Piper Sandler	Boost Target		$54.00 ➝ $55.00	High
5/5/2022	Stifel Nicolaus	Boost Target		$31.00 ➝ $33.00	Low
4/1/2022	SVB Leerink	Lower Target	Market Perform	$29.00 ➝ $26.00	High
3/1/2022	Guggenheim	Initiated Coverage	Buy	$64.00	Medium
2/28/2022	Citigroup	Initiated Coverage	Sell	$26.00	Medium
2/25/2022	SVB Leerink	Lower Target	Market Perform	$34.00 ➝ $29.00	Medium
2/1/2022	Bank of America	Downgrade	Buy ➝ Underperform	$40.00 ➝ $30.00	High
12/17/2021	SVB Leerink	Lower Target	Market Perform	$36.00 ➝ $34.00	High
12/14/2021	William Blair	Upgrade	Market Perform ➝ Outperform		High
12/10/2021	BMO Capital Markets	Initiated Coverage	Buy	$65.00	Medium
12/8/2021	SVB Leerink	Lower Target	Market Perform	$39.00 ➝ $36.00	High
11/4/2021	Needham & Company LLC	Lower Target	Buy	$84.00 ➝ $60.00	Medium
11/4/2021	SVB Leerink	Boost Target	Market Perform	$38.00 ➝ $39.00	Medium
10/12/2021	Morgan Stanley	Lower Target	Underweight	$33.00 ➝ $31.00	Low
8/19/2021	BMO Capital Markets	Lower Target	Outperform	$70.00 ➝ $68.00	Low
8/5/2021	SVB Leerink	Lower Target	Market Perform	$41.00 ➝ $38.00	High
7/16/2021	Morgan Stanley	Lower Target	Underweight	$35.00 ➝ $33.00	Medium
5/14/2021	SVB Leerink	Boost Target	Market Perform	$36.00 ➝ $41.00	Medium
5/7/2021	UBS Group	Upgrade	Sell ➝ Neutral	$33.00 ➝ $37.50	High
5/6/2021	Morgan Stanley	Lower Target	Underweight	$38.00 ➝ $35.00	High
4/19/2021	Morgan Stanley	Lower Target	Underweight	$43.00 ➝ $38.00	Low
4/5/2021	UBS Group	Reiterated Rating	Reduce		High
3/23/2021	BMO Capital Markets	Lower Target	Positive ➝ Outperform	$90.00 ➝ $76.00	High
3/23/2021	Needham & Company LLC	Lower Target	Buy	$95.00 ➝ $86.00	High
3/23/2021	SVB Leerink	Lower Target	Market Perform	$50.00 ➝ $36.00	High
3/23/2021	Morgan Stanley	Lower Target	Underweight	$50.00 ➝ $43.00	High
3/23/2021	Barclays	Lower Target	Equal Weight	$52.00 ➝ $47.00	High
3/23/2021	Royal Bank of Canada	Lower Target	Positive ➝ Outperform	$76.00 ➝ $65.00	High
3/22/2021	Piper Sandler	Lower Target	Neutral	$55.00 ➝ $45.00	High
3/16/2021	UBS Group	Reiterated Rating	Sell	$33.00	Medium
3/1/2021	Barclays	Upgrade	Underweight ➝ Equal Weight	$50.00 ➝ $52.00	Low
2/25/2021	Morgan Stanley	Boost Target	Underweight	$49.00 ➝ $50.00	High
2/24/2021	Piper Sandler	Lower Target	Neutral	$60.00 ➝ $55.00	High
12/15/2020	UBS Group	Initiated Coverage	Sell	$34.00	Medium
12/15/2020	Cowen	Upgrade	Market Perform ➝ Outperform		High
11/5/2020	Morgan Stanley	Lower Target	Underweight	$50.00 ➝ $49.00	High
11/5/2020	SVB Leerink	Lower Target	Market Perform	$56.00 ➝ $50.00	High
10/13/2020	Morgan Stanley	Lower Target	Underweight	$54.00 ➝ $50.00	Low
10/7/2020	Oppenheimer	Reiterated Rating	Buy	$69.00	Low
9/22/2020	Oppenheimer	Initiated Coverage	Buy	$69.00	High
9/22/2020	Cantor Fitzgerald	Boost Target	Neutral	$56.00 ➝ $59.00	High
9/14/2020	JPMorgan Chase & Co.	Initiated Coverage	Neutral		Medium
9/8/2020	Citigroup	Lower Target		$74.00 ➝ $78.00	Low
9/2/2020	Benchmark	Initiated Coverage	Hold		Medium
9/1/2020	Royal Bank of Canada	Boost Target		$71.00 ➝ $73.00	Low
9/1/2020	SVB Leerink	Boost Target	Market Perform	$54.00 ➝ $56.00	Medium
9/1/2020	Oppenheimer	Lower Target	Outperform	$74.00 ➝ $69.00	Medium
9/1/2020	Needham & Company LLC	Boost Target	Buy	$89.00 ➝ $91.00	Medium
8/30/2020	Oppenheimer	Initiated Coverage	Buy	$74.00	High
8/10/2020	Citigroup	Lower Target	Buy	$80.00 ➝ $78.00	High
8/6/2020	Morgan Stanley	Lower Target	Underweight	$56.00 ➝ $54.00	Low
8/6/2020	Oppenheimer	Reiterated Rating	Buy		Low
8/5/2020	Needham & Company LLC	Initiated Coverage	Buy	$89.00	Low
8/5/2020	William Blair	Reiterated Rating	Hold		Low
7/15/2020	Morgan Stanley	Boost Target	Underweight	$51.00 ➝ $56.00	Low
7/15/2020	Needham & Company LLC	Reiterated Rating	Buy	$89.00	Medium
6/10/2020	William Blair	Reiterated Rating	Hold		High
6/5/2020	Citigroup	Boost Target	Buy	$71.00 ➝ $80.00	High
5/12/2020	Royal Bank of Canada	Initiated Coverage	Outperform	$71.00	Medium
5/7/2020	Morgan Stanley	Boost Target	Underweight	$48.00 ➝ $51.00	High
5/7/2020	Oppenheimer	Lower Target	Outperform	$77.00 ➝ $74.00	High
5/6/2020	Needham & Company LLC	Reiterated Rating	Buy	$89.00	High
4/9/2020	Citigroup	Lower Target	Buy	$73.00 ➝ $71.00	Low
3/26/2020	Cantor Fitzgerald	Lower Target	Neutral	$65.00 ➝ $56.00	High
3/9/2020	JPMorgan Chase & Co.	Boost Target	Neutral	$58.00 ➝ $60.00	Low
3/5/2020	Citigroup	Initiated Coverage	Buy	$73.00	High
2/27/2020	Piper Sandler	Lower Target	Neutral	$70.00 ➝ $65.00	High
1/30/2020	BMO Capital Markets	Reiterated Rating	Buy	$86.00	High
1/24/2020	William Blair	Reiterated Rating	Hold		Low
12/31/2019	Bank of America	Reiterated Rating	Buy	$70.00	Medium
12/23/2019	Needham & Company LLC	Reiterated Rating	Buy	$87.00	Low
12/13/2019	Needham & Company LLC	Reiterated Rating	Buy	$87.00	Medium
12/12/2019	Oppenheimer	Initiated Coverage	Buy	$77.00	Low
11/14/2019	William Blair	Initiated Coverage	Market Perform		Low
11/13/2019	Bank of America	Initiated Coverage	Buy	$70.00	Medium
11/7/2019	Piper Sandler Companies	Lower Target	Neutral	$75.00 ➝ $70.00	Medium
11/7/2019	Needham & Company LLC	Reiterated Rating	Buy	$87.00	Low
11/7/2019	Morgan Stanley	Downgrade	Equal ➝ Equal Weight	$63.00 ➝ $48.00	Low
11/7/2019	Cowen	Reiterated Rating	Hold		Low
10/16/2019	Cowen	Reiterated Rating	Hold		High
10/15/2019	Cantor Fitzgerald	Set Target	Hold	$65.00	N/A
10/11/2019	Morgan Stanley	Lower Target	Equal Weight	$68.00 ➝ $63.00	Medium
10/10/2019	Wells Fargo & Company	Boost Target	Outperform	$90.00 ➝ $120.00	Medium
10/9/2019	Needham & Company LLC	Set Target	Buy	$87.00	Low
9/23/2019	Wells Fargo & Company	Reiterated Rating	Buy		Medium
9/10/2019	Sanford C. Bernstein	Upgrade	Market Perform ➝ Outperform	$80.00	High
8/7/2019	Evercore ISI	Set Target	Hold	$76.00	Low
7/24/2019	BMO Capital Markets	Lower Target	Outperform	$96.00 ➝ $95.00	Low
5/24/2019	Piper Sandler Companies	Set Target	Hold	$75.00	Medium

(Data available from 4/28/2019 forward)

News Sentiment Rating

0.80 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

18 very positive mentions
7 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

10/1/2023

6 very positive mentions
5 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/31/2023

7 very positive mentions
8 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

11/30/2023

11 very positive mentions
12 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

12/30/2023

16 very positive mentions
12 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

1/29/2024

19 very positive mentions
30 positive mentions
0 negative mentions
2 very negative mentions

Mentions as of

2/28/2024

10 very positive mentions
15 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

3/29/2024

12 very positive mentions
17 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

4/28/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Today's Range

Now: $41.59

$41.36

$42.28

50 Day Range

MA: $43.28

$40.68

$47.41

52 Week Range

Now: $41.59

$34.32

$54.44

Volume

556,093 shs

Average Volume

856,032 shs

Market Capitalization

$6.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

Frequently Asked Questions

What sell-side analysts currently cover shares of Ionis Pharmaceuticals?: The following equities research analysts have issued research reports on Ionis Pharmaceuticals in the last year: Bank of America Co., Barclays PLC, Citigroup Inc., JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, The Goldman Sachs Group, Inc., VNET Group, Inc., William Blair, and Wolfe Research.
View the latest analyst ratings for IONS.
What is the current price target for Ionis Pharmaceuticals?: 13 Wall Street analysts have set twelve-month price targets for Ionis Pharmaceuticals in the last year. Their average twelve-month price target is $56.08, suggesting a possible upside of 34.8%. Oppenheimer Holdings Inc. has the highest price target set, predicting IONS will reach $75.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $28.00 for Ionis Pharmaceuticals in the next year.
View the latest price targets for IONS.
What is the current consensus analyst rating for Ionis Pharmaceuticals?: Ionis Pharmaceuticals currently has 1 sell rating, 3 hold ratings, 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for IONS.
What other companies compete with Ionis Pharmaceuticals?: Other companies that are similar to Ionis Pharmaceuticals include Madrigal Pharmaceuticals, Alkermes, Amicus Therapeutics, Geron and Dynavax Technologies. Learn More about companies similar to Ionis Pharmaceuticals.
How do I contact Ionis Pharmaceuticals' investor relations team?: Ionis Pharmaceuticals' physical mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company's listed phone number is (760) 931-9200 and its investor relations email address is [email protected]. The official website for Ionis Pharmaceuticals is www.ionispharma.com. Learn More about contacing Ionis Pharmaceuticals investor relations.

Ionis Pharmaceuticals - IONS Stock Price Target and Predictions

Analyst Price Target for IONS

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.80 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Ionis Pharmaceuticals?

What is the current price target for Ionis Pharmaceuticals?

What is the current consensus analyst rating for Ionis Pharmaceuticals?

What other companies compete with Ionis Pharmaceuticals?

How do I contact Ionis Pharmaceuticals' investor relations team?